Quo vadis, biomarkers?

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 6, 2014, Pages 761-764

  Plebani, Mario ^a   Melichar, Bohuslav ^b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

HUMAN; LABORATORY PERSONNEL; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUMOR DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; METHODOLOGY; TRANSLATIONAL RESEARCH;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84903578203     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0100     Document Type: Review

References (20)

1. Plebani M, Lippi G. Personalized (laboratory) medicine: A bridge to the future. Clin Chem Lab Med 2013;51:703-6
2. Lippi G, Plebani M. Biomarker research and leading causes of death worldwide: A rather feeble relationship. Clin Chem Lab Med 2013;51:1691-3
3. Davis JC, Furstenthal L, Desai AA, Norris T, Sutaria S, Fleming E, et al. The microeconomics of personalized medicine: Today's challenge and tomorrow's promise. Nature Rev Drug Discov 2009;8:279-86
4. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-67
5. Poste G. Bring on the biomarkers. Nature 2011;469:156-7
6. Pavlou MP, Diamandis EP, Blasutig IM. The long journey of cancer biomarkers. Clin Chem 2013;59:147-57
7. Simon R. Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility. Eur J Cancer 2008;44:2707-13
8. Anderson NL, Ptolemy AS, Rifai N. The riddle of protein diagnostics: future bleak or bright. Clin Chem 2013;59: 194-7
9. Diamandis EP. Quality of the scientific literature: All that glitters is not gold. Clin Biochem 2006;39:1109-11 (Pubitemid 44848324)
10. Rifai N, Watson ID, Miller G. Commercial immunoassays in biomarkers studies: researchers beware! Clin Chem Lab Med 2013;51:249-51
11. Prassas I, Diamandis EP. Translational researchers beware! Unreliable commercial immunoassays (ELISAs) can jeopardize your research. Clin Chem Lab Med 2014;52:765-6
12. Plebani M. Evaluating laboratory diagnostic tests and translational research. Clin Chem Lab Med 2010;48:983-8
13. Vaught J, Lockhart NC. The evolution of biobanking best practices. Clin Chim Acta 2012;413:1569-75
14. Korevaar DA, van Enst WA, Spijker R, Bossuyt PM, Hooft L. Reporting quality of diagnostic accuracy studies: A systematic review and meta-analysis of investigations on adherence to STARD. Evid Based Med 2013 Dec 24. [Epub ahead of print]
15. Melichar B. Laboratory medicine and medical oncology: The tale of two Cinderellas. Clin Chem Lab Med 2013;51:99-112
16. Melichar B, Plebani M. Targeted therapy for HER-2: personalized medicine for her, too. Clin Chem Lab Med 2012;50:1-4
17. Cunningham D, Hurnblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
18. Melichar B, Němcová I. Eye complications of cetuximab therapy. Eur J Cancer Care 2007;16:439-43.
19. Diamandis EP. A repository for "rare" tumor markers? Clin Chem Lab Med 2014;52:795-7.
20. Plebani M, Marincola FM. Research translation: A new frontier for clinical laboratories. Clin Chem Lab Med 2006; 44:1303-12. (Pubitemid 44706707)